NETRF named Michael German, MD as the NETRF Petersen Investigator for his project entitled, “Treating Neuroendocrine Tumors via Synthetic Lethality” The objective his research is to analyze how the UPR-MEN1-MAPK pathways interact to control neuroendocrine cell survival and death, and to evaluate synthetic lethal interactions in a patient-derived xenograft tumor model of pancreatic neuroendocrine tumors.